Business
HLS Therapeutics Announces Reimbursement for Vascepa® under Nova Scotia's Provincial Drug Plan
HLS Therapeutics Announces Reimbursement for Vascepa® under Nova Scotia's Provincial Drug Pl...
About this update from Hls Therapeutics, Inc.
[{"type":"text","content":"\n\n\n\n HLS Therapeutics Announces Reimbursement for Vascepa® under Nova Scotia's Provincial Drug Plan\n \n\n /* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n \n\n\n\n\n\n Canada NewsWire\n \n\n\n\n\n\n\n Vascepa is now available to more than 95% of Canadians who are eligible and covered by a public plan or private insurance\n \n\n\n\n\n\n\n TORONTO\n \n\n ,\n \n\n July 2, 2025\n \n\n /CNW/ - HLS Therapeutics Inc. (\"HLS\" or the \"Company\") (TSX: HLS), a pharmaceutical company focusing on addressing unmet needs in the treatment of psychiatric disorders and cardiovascular disease, announces that it has entered into a Product Listing Agreement (\"PLA\") with the province of\n \n Nova Scotia\n \n , for the listing and public reimbursement of Vascepa (icosapent ethyl). The PLA with Nova Scotia Pharmacare is effective\n \n July 1, 2025\n \n .\n \n\n Under the terms of the PLA, Vascepa will be reimbursed as an exception status product by the\n \n Nova Scotia\n \n formulary for the secondary prevention of cardiovascular events (cardiovascular death, non-fatal myocardial infarction, non-fatal stroke, coronary revascularization or hospitalization for unstable angina) in statin-treated patients with established cardiovascular disease and elevated triglycerides.\n \n\n \"The PLA with Nova Scotia Pharmacare will significantly improve access and reimbursement for Vascepa in\n \n Atlantic Canada\n \n ,\" said\n \n Craig Millian\n \n , CEO of HLS. \"This milestone, combined with the recent in-licensing of two new products into our cardiovascular portfolio, supports our efforts to position HLS as a leading Canadian-based company focused on reducing cardiovascular risk for Canadians.\"\n \n\n Vascepa is now available to more than 95% of eligible patients covered by public plans and private insurance in\n \n Canada\n \n .\n \n\n\n ABOUT VASCEPA (ICOSAPENT ETHYL) CAPSULES\n \n\n Vascepa capsules are the first-and-only prescription treatment comprised solely of the active ingredient, icosapent ethyl (IPE), a unique form of eicosapentaenoic acid. Vascepa was approved by Health Canada and added...